We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to identify the maximum tolerated dose (MTD) of wSKd. Secondary endpoints included overall response rate (ORR), progression-fr …
Provided to YouTube by NAXOS of AmericaOctober · North Texas Wind SymphonyNorth Texas Wind Symphony: Passions℗ 2005 KlavierReleased on: 2005-01-01Composer: E…
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors…
PURPOSE Hospice is underutilized by patients with hematologic malignancies (HM), and when patients are referred, they are typically more ill, hospitalized, and with shorter length…
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
A prospective repository of longitudinal, real-world patient-reported outcomes (PRO) and quality of life data for patients with blood disorders.
Abstract. Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen re
Abstract. Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen re
PURPOSE Hospice is underutilized by patients with hematologic malignancies (HM), and when patients are referred, they are typically more ill, hospitalized, and with shorter length…
